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Summary Although women with breast cancer tend to have a greater proportion of their circulating
oestradiol non-protein bound and albumin bound, and less SHBG-bound, than controls, it remains uncertain
whether this has an aetiological role or is an effect of the tumour. Oestradiol and its binding to serum proteins
was investigated: (a) in relation to risk factors for breast cancer in a normal population; (b) in women with
proliferative benign breast disease as a risk group for breast cancer, and women with non-proliferative benign
breast disease as a low risk group, as well as breast cancer patients. The strongest associations were with body
mass index; the greater the body mass the greater the bioavailability of oestradiol. Changes in relation to age
at menarche and menopause could have been a function of body mass. An interesting change with age was
noted with a fall in bioavailability over the menopausal years. There was no relationship apparent for parity,
age at first full term pregnancy, family history or country of birth. Similar differences in oestradiol binding
between cases and controls were seen for patients with breast cancer, benign epithelial hyperplasia and
fibrocystic disease without proliferative changes, but these were not significant. This study provides limited
support for the concept that oestradiol binding has an aetiological role in the development of breast cancer.
For long it has been believed that many forms of breast
disease, particularly breast cancer, have a hormonal origin.
In particular, because of its profound stimulatory influence
on breast ductal epithelium, it was thought that oestradiol
must play a central role. Differences in the total concentra-
tion of oestradiol, however, are generally not apparent
between patients with breast cancer and normal controls,
particularly for premenopausal women (Moor et al., 1982;
Reed et al., 1983; Ota et al., 1986). In recent years the
concept of bioavailability of oestradiol has been recognised,
oestradiol being mostly loosely bound to albumin, about
one-third tightly bound to sex hormone binding globulin
(SHBG) and a few per cent non-protein bound or 'free'
(Siiteri et al., 1982). It is the free and albumin bound com-
ponents which are available to the tissues and are therefore
the functionally important proportion of oestradiol. A
number of studies have demonstrated that the proportions of
free and albumin bound oestradiol are higher in breast
cancer patients (Moore et al., 1982; Reed et al., 1983; Ota et
al., 1986).
Postulating an aetiological role is difficult as the changes in
binding may be an effect of the disease rather than cause. To
try to provide further evidence we have investigated associa-
tions between known risk factors and oestradiol binding in a
study population consisting of breast cancer patients, patients
with histologically categorised benign breast disease and 'nor-
mal' community controls. The benign breast disease patients
were grouped into those who histologically had evidence of
epithelial hyperplasia and hence had an increased risk of
subsequently developing breast cancer, and those with only
changes of fibrosis and cystic disease who should not have
had any increase in risk (Page et al., 1978).
Methods
Subjects
Five hundred and eighteen women were studied between
February 1985 and August 1987. Cases were identified from
the pathology reports of the combined Hospital and Univer-
sity Pathology Services and the State Health Laboratory
Services at the Queen Elizabeth II Medical Centre, Perth,
Western Australia. The histology was reviewed by a
pathologist (A.R.) who categorised the cases into invasive
breast cancer, benign epithelial hyperplasia with or without
atypia, or benign fibrocystic disease without any evidence of
epithelial proliferation. Patients with other breast pathologies
were not included. Each case was matched by age (5-year age
group) and area of residence (electoral district) with a control
randomly chosen from the electoral roll.
All subjects were contacted by an identical letter requesting
their participation in a health survey, but without specific
mention of breast disease. Cases were not contacted until
consent from their surgeon had been obtained, and not until
3 months had elapsed from the time of their surgery. Failure
to respond to the letter was followed by a further letter and
telephone call. If a control refused participation a replace-
ment was chosen from the electoral role.
Data collection
All women were interviewed at home by a single interviewer
(E.N.). Data relating to risk factors for breast disease were
gathered on a previously developed questionnaire, including
details of menstrual status, country of birth, oral contracep-
tive and other hormonal use, family history of breast cancer,
age at menarche and menopause, parity and age at first child.
Height and weight were measured.
Hormone assay
A single 40 ml fasting blood sample was taken between
8.00 a.m. and 12 midday, the serum was promptly separated
and glass vials each containing I ml of serum were frozen
and stored at - 70°C. The specimens were stored at - 70°C
as oestradiol tends to dissociate with time from its binding
proteins when stored at - 20°C (Langley et al., 1985). In
addition, the duration of storage was similar for cases and
controls. Premenopausal women who had not had a hysterec-
tomy had their blood collected on days 21 or 22 of the
menstrual cycle. The specimens were assayed in batches for
total concentration of oestradiol, progesterone and sex hor-
mone binding globulin (SHBG) by radio-immunoassay using
commercial kits, with cases and controls being spread
between batches. In addition, women whose menopausal
status was uncertain had the concentration of follicle
stimulating hormone (FSH) assayed. Menopausal status was
thus determined using the concentrations of FSH, oestradiol
and progresterone. The coefficients of variation between
assays were oestradiol 9%, SHBG 9%, FSH 7% and pro-
gesterone 10%. The non-protein bound (free) proportion of
oestradiol was determined by rate dialysis (Willcox et al.,
1983) and the albumin bound component by the same
method after heat treatment of serum at 60°C for I h (Ham-
mond et al., 1982).
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Statistical methods
The data were loaded into the data base of a personal
computer and statistical analyses performed using the prog-
ram Epilog (Epicentre Software, Pasadena, CA, USA).
Estimates of relative risk and associated 95% confidence
limits were determined by conditional logistic regression for
each of the hormonal variables and for each of the disease
groups studied, i.e. patients with invasive breast cancer,
patients with benign epithelial hyperplasia and patients with
benign fibrocystic disease without evidence of epithelial
hyperplasia. Each hormonal variable was recoded into approx-
imately equal quartiles and the relative risks were expressed
for each of the quartiles in relation to the lowest quartile. As
body mass was found to have a profound effect on oestrogen
binding, all estimates of relative risk were adjusted for body
mass index.
Associations between risk factors for breast cancer and
each of the hormonal variables were determined by one-way
analysis of variance after categorising the risk factor into
relevant sub-groups (F test), utilising one-sided P values. In
addition, associations between risk factors and the hormonal
variables were tested by linear regression analysis and after
adjusting for Quetelet's index. Analyses were repeated after
logarithmic transformation of the hormonal variable. These
associations were determined using only the control popula-
tion.
Women taking the oral contraceptive pill (25), oestrogen
replacement therapy (19), tamoxifen (15) or undergoing
cytotoxic therapy (1) were excluded from analyses. In addi-
tion, the group of premenopausal women who had had a
hysterectomy were excluded from analyses involving total
concentration of oestradiol or progesterone as their stage of
the menstrual cycle could not be determined (66).
Results
Patients and controls
One hundred and eight patients with invasive breast cancer,
96 patients with benign epithelial hyperplasia of the breast
and 96 patients with fibrocystic disease of the breast but
without epithelial hyperplasia were studied. The patients with
epithelial hyperplasia and fibrocystic disease shared a com-
mon control subject, and in total 214 community control
subjects were studied. Seventy-eight per cent of contactable
control subjects agreed to take part in the study while 84%
of contacted patients took part.
Age
Both variables of bioavailability of oestradiol, i.e. the free
and albumin bound components, showed the same pattern of
being high in the young age group and progressively falling,
reaching a low in the perimenopausal years, thereafter rising
as age increased. This pattern was supported by the changes
in SHBG concentration which were diametrically opposite,
reaching a peak in the perimenopausal years (Figure 1 and
Table I). Adjusting for QI improved the statistical
significance for these associations (free oestradiol P = 0.0156,
albumin-bound oestradiol P = 0.0116, SHBG P = 0.5297).
Country ofbirth
There were few Europe-born and Asia-born women. There
was little difference between the other countries of birth for
any of the hormonal variables. This applied even after re-
analysis for those who had been in Australia for less than 15
years (Table I).
Age at menarche
The recalled age at menarche was plotted for each of the
hormonal variables (Figure 2). The only pattern to emerge
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Figure 1 The proportion of free and albumin bound oestradiol,
and concentration of SHBG plotted by age in 10-year age groups
for normal population, showing a fall in oestradiol binding and a
rise in SHBG in the perimenopausal years. These changes appear
to be independant of body mass changes. (Mean ± s.e.m.)
was a stepwise fall in SHBG concentration for decreasing
recalled age at menarche. This was not statistically significant
(Table I). Similarly, when analysed by linear regression there
were no significant associations with the hormonal variables.
Age at menopause
The recalled age at menopause was plotted for each of the
hormonal variables (Figure 2). For both the total concentra-
tion of oestradiol and the proportion of oestradiol which was
bioavailable (free and albumin bound) there was a progres-
sive stepwise increase with increasing age at menopause.
Similarly, for the concentration of SHBG there was a reduc-
tion in SHBG with increasing age at menopause (Table I).
After adjusting for QI, however, these patterns largely disap-
peared, as did any trend to statistical significance (free oest-
radiol P = 0.8943, albumin bound oestradiol P = 0.8458,
SHBG P = 0.8058). Linear regression analysis was not
significant for any of the hormonal variables.
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Figure 2 The proportion of free and albumin-bound oestradiol,
and concentration of SHBG plotted against the recalled age at
menarche (a) and age at menopause (b) for the population of
normal women. The apparent rise in oestradiol binding and fall
in SHBG with increasing age at menopause largely disappeared
after adjusting for body mass. (Mean ± s.e.m.)
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Table I Oestrogen variable (mean ± s.e.m.)
Total oestradiol Albumin bound
Premenopausal Post-menopausal 'Free' oestradiol oestradiol SHBG
Risk variable No. (pmoll-') (pmollt') (%) (%) (nmolI-')
Age (years)
30 or less
31 -40
41 -50
51 -60
61 or more
7
30
69
32
51
Country of birth
NZ
UK
Europe
Asia
Australia
Age at menarche (years)
11 or less
12-13
14-15
16 or more
Age at menopause (years)
40 or less
41 -45
46-50
51 or more
Quetelet's index (kg m-2)
20 or less
21 -24
25-28
29 or more
Parity (no. children)
0
l
2
3
4 or more
Age at first pregnancy (years)
20 or less
21 -24
25-28
29 or more
Family history
No FH
2nd degree
1st degree
13
48
7
7
108
23
83
65
16
17
16
29
19
16
71
57
43
22
22
46
55
44
25
65
36
23
164
12
12
376 75
362 35
432 47
558 191
329± 37
255± 55
449± 50
398± 96
383± 27
479 107
391 52
P=0.715
538 113
356± 36
461 98
374± 47
P=0.348
432± 89
326± 55
289± 41
454± 51
512 120
P= 0.219
254± 35
502± 67
436± 97
251 + 70
P=0.104
(insufficient numbers for
separate analyses)
P = statistical significance based on unadjusted determination by analysis of variance.
Body mass index
Body mass index as determined by Quetelet's index (kg m-2)
was highly significantly related to the binding of oestradiol.
With increasing obesity there was a progressive rise in the
proportion of free and albumin bound oestradiol, and a
progressive reduction in the SHBG concentration (Figure 3).
For post-menopausal women there was a progressive rise in
total oestradiol with increasing obesity, but this did not
apply for premenopausal women (Table I). Linear regression
analysis confirmed these associations.
Parity
There were no associations apparent between the variables of
oestradiol binding and the number of full term pregnancies.
Age atfirst pregnancy
As with parity there were no associations between oestradiol
binding and the age at first pregnancy although again there
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Figure 3 Body mass and oestradiol binding. The proportion of
free and albumin-bound oestradiol plotted against body mass
(Quetelet's index). Strong associations are apparent.
(Mean ± s.e.m.)
21.1 4.6
33.6 6.0
26.1 ±4.8
37.2 12.6
35.0± 6.6
10.0± 5.0
12.4± 5.2
20.7± 3.0
19.7± 6.4
24.3± 4.5
29.5 5.6
21.2± 6.2
P= 0.668
19.5 4.6
18.8 4.3
24.6± 4.4
34.1 8.8
P = 0.277
19.2± 4.8
24.0± 4.1
26.0± 5.6
28.4± 6.6
P= 0.884
13.3 13.4
33.5 10.6
33.9 7.3
22.2 5.9
22.2 3.9
P=0. 169
19.9± 5.5
25.6 3.7
29.3 8.2
33.8 10.1
P=0.684
1.40±0.10
1.37 0.05
1.27 0.03
1.30±0.04
1.33±0.04
P= 0.255
1.30 + 0.08
1.31 +0.03
1.35 + 0.09
1.22 0.08
1.31 +0.02
1.30 + 0.05
1.32 0.03
1.29 0.03
1.31 0.05
P=0.894
1.20 0.06
1.22 0.06
1.34 0.04
1.35 0.05
P=0.081
1.22 0.05
1.22 0.03
1.32 0.03
1.47 + 0.03
P = 0.0001
1.27 + 0.06
1.35 0.04
1.26 0.03
1.33 0.04
1.32 0.03
P = 0.402
1.25 + 0.05
1.32 0.03
1.29 0.04
1.34 0.04
P= 0.538
1.31 0.02
1.24 + 0.05
1.32 0.06
69.3 6.2
64.4 2.4
60.9± 1.2
63.7 + 2.2
67.5 2.0
P=0.047
64.2 3.4
62.6± 1.7
63.9 4.5
64.0 4.5
64.9 1.3
65.3 _ 2.6
65.0± 1.5
62.0± 1.3
64.8 3.0
P= 0.483
59.8 _ 2.7
65.1 _ 3.4
66.1 1.9
68.7 3.4
P= 0.179
59.4 3.2
59.0± 1.5
65.5 1.5
71.9± 1.5
P = 0.0001
64.2 3.1
66.5 2.4
61.9± 1.6
65.3± 1.9
63.1 _ 1.8
P= 0.547
61.1 _2.5
63.7± 1.5
63.9 2.2
65.2 2.9
P=0.701
64.5± 1.0
58.2 2.0
62.9 3.2
63.7± 6.7
71.2± 5.1
77.2± 5.7
69.9 7.8
65.1 6.3
P= 0.625
69.1 13.6
70.8 5.8
62.3 15.2
68.2 11.6
70.9 4.2
66.1 8.6
68.7± 4.6
74.8± 5.0
75.7± 14.1
P=0.745
77.3 11.0
70.3 8.5
57.9 6.0
62.1 12.4
P = 0.439
89.2 12.2
82.5± 5.2
68.0± 4.8
49.5i 5.8
P = 0.0002
69.3 6.3
60.8 8.6
76.4 6.1
75.9 6.8
66.3± 3.1
P= 0.516
77.1 8.7
74.3 5.5
69.0 6.6
69.9± 10.5
P= 0.877
71.9± 3.4
71.6 8.3
61.7_ 10.3306 D.M. INGRAM et al.
did appear to be an association with the total concentration
of oestradiol for post-menopausal women. Post-menopausal
women who had a late age at first pregnancy had a higher
concentration of total oestradiol but this again was not
significant (Table I).
Family history
There did not appear to be any association between family
history of breast cancer and oestradiol binding although
women who had a first degree relative who had had breast
cancer had a rather lower SHBG concentration. This was not
statistically significant. The number of women in the study
group with a family history of breast cancer was relatively
small and when divided into sub-groups, e.g. pre and post-
menopausal or multiple relatives, the numbers were too small
to be meaningful (Table I).
Benign breast disease
The relative risks of cases in relation to controls were deter-
mined for each of the hormonal variables for breast cancer
patients, for patients with benign epithelial hyperplasia and
for patients with fibrocystic disease of the breast without
evidence of proliferative changes (Table II). Because of the
influence of obesity and age on oestrogen binding, all
estimates of relative risk were adjusted for Quetelet's index
and age and the lines of regression for each hormonal
variable against Quetelet's index were plotted separately for
cases and controls (Figure 4). Similar patterns were apparent
for the cancer patients as for the patients with benign
epithelial hyperplasia and those with fibrocystic disease. In
each situation the cases had a higher level of free and
albumin bound oestradiol at all levels of obesity compared to
their controls, and conversely had lower concentrations of
SHBG at all levels of obesity compared to controls. In none
of these situations, however, was statistical significance
reached.
Discussion
One of the problems with case-control studies is knowing if
differences between patients and their controls relate to the
cause of the disease or occur because of the disease process.
As regards the role of oestradiol and its binding to serum
Table II Estimations of relative risks for each of the disease study
groups in relation to controls, after adjusting for age and Quetelet's
index.
Benign epithelial Fibrocystic disease
Breast cancer hyperplasia ofthe breast
Free oestradiol
1st quartile 1.0 1.0 1.0
2nd quartile 2.2 3.0 2.2
3rd quartile 2.0 2.3 2.9
4th quartile 0.8 2.3 2.2
x2 (3 d.f.) 6.10 4.74 5.02
Albumin bound
oestradiol
1st quartile 1.0 1.0 1.0
2nd quartile 1.4 1.3 2.0
3rd quartile 1.1 1.4 1.6
4th quartile 1.4 2.3 2.0
x2 (3 d.f.) 0.64 3.08 2.20
SHBG concent-
ration
Ist quartile 1.0 1.0 1.0
2nd quartile 2.0 1.1 1.6
3rd quartile 1.5 0.6 0.4
4th quartile 2.0 0.9 0.7
X2 (3 d.f.) 2.42 2.16 7.22
The estimates have been undertaken for the proportion of free
oestradiol, theproportion bound to albumin, and for theconcentration
of SHBG. Statistical significance was not reached in any situation.
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Figure 4 Comparison of oestradiol binding for patients and
controls at differing levels of obesity. The lines of regression for
patients (heavy lines) and controls (fine lines) plotted for each of
the disease states studied: breast cancer, benign epithelial hyper-
plasia and fibrocystic disease of the breast. At all levels of body
mass cases had a greater proportion of their oestradiol free and
albumin body and a lower SHBG concentration compared to
controls. a, breast cancer; b, benign epithelial hyperplasia; c,
fibrocystic disease of the breast.
proteins in the aetiology of carcinoma of the breast, we have
attempted to resolve the problem by: (a) looking at
differences in these hormonal variables for differing levels of
risk in a control population; (b) undertaking a series of
case-control studies, not only for patients with breast cancer
but also for patients with histologically proven benign
epithelial hyperplasia who are thus at risk of developing
breast cancer, and also for a low risk group, patients with
fibrocystic disease but with no proliferative changes on his-
tology (Page et al., 1978). If the trends seen in the breast
cancer patients were also reflected in the high risk benign
breast disease group, then this would be further evidence that
oestradiol binding plays an aetiological role.
From the data presented in this paper, although a number
of trends emerge, there is little conclusive evidence of associa-
tions between oestradiol and its binding and risk factors for
breast cancer. Of all the variables of risk studied, body mass
had by far the strongest association (de Moor & Joossens,
1970) and may in fact, as discussed below, be responsible for
many of the trends seen with the other risk factors. We have
demonstrated that women with a large body mass have a
much greater proportion of their oestradiol bioavailable, i.e.
free or albumin bound. Obesity itself is not a strong risk
factor for breast cancer, de Waard et al. (1974) finding that
only women over 65 who weighed more than 80 kg had an
increased risk for breast cancer, while our own studies have
shown that women who gain more than 10kg over their
reproductive years have an increased relative risk which is
approximately two-fold (Ingram et al., 1989). It should be
noted that any risk, however small, if it is widely prevalent in
the study population (as is obesity), can have a major impact
on the incidence of the disease.
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The association of oestradiol binding with age is interest-
ing if one considers the relationship between breast cancer
incidence and age in Western population. There is a steep
rise to age 40 and thereafter the incidence plateaus until the
post-menopausal years when it rises again (Fleming et al.,
1981). This fits very nicely with the changes in oestradiol
binding demonstrated in Figure 1, where the proportion of
bioavailable oestradiol is high in the premenopausal years,
falls over the menopausal years and is high again in later life.
SHBG follws a converse pattern. One possibility is that the
post-menopausal rise in free and albumin bound oestradiol
(and fall in SHBG) occurs because of weight gain in these
years, but adjusting for body mass index appeared to streng-
then rather than reduce these associations.
The patterns of rising free and albumin bound oestradiol
and falling SHBG with increase in age at menopause, and
fall in SHBG with early age at menarche, support these
hormonal changes as having a role in breast cancer develop-
ment as early age at menarche and late age at menopause are
well recognised risk factors (Pike et al., 1981). Again, how-
ever, these changes could be accounted for by obesity as we
have demonstrated in a previous study that obese women are
more likely to have an early age of menarche and late age at
menopause (Ingram et al., 1989). Moore et al. (1987)
similarly demonstrated that late menarche was associated
with increased SHBG and adjusting for QI reduced the mag-
nitude of the association; we have demonstrated here that
adjusting for body mass reduced the assocation between age
at menopause and oestradiol binding and SHBG. Little can
be made of the other variables of risk and their associations
with oestradiol and its binding. With the country of birth,
even after taking out those who have been in Australia for
more than 15 years, there were no significant differences
although the numbers were small for all other than United
Kingdom immigrants. Parity and age at first full term preg-
nancy were not significantly associated with the hormonal
variables while the numbers of women in the control group
with a family history of breast cancer were small and it
would require a much larger study to evaluate this variable.
As regards differences in oestradiol binding between cases
with breast cancer, benign epithelial hyperplasia or fibrocys-
tic disease and their respective controls, there is a remarkably
similar pattern throughout, in that after adjusting for body
mass, for each group the free and albumin bound propor-
tions of oestradiol are higher for the breast disease patients
than controls, and the SHBG concentrations are correspond-
ingly lower (Figure 4). This suggests that increased bio-
availability of oestradiol may promote breast cancer by
stimulating epithelial growth, although while the estimations
of relative risk were correspondingly increased (for free and
albumin-bound oestradiol) and lower (for SHBG), in no case
did they reach statistical significance.
In conclusion, apart from the association between oest-
radiol binding and body mass, we have been unable to
provide strong evidence that the degree of oestradiol binding
to serum proteins is associated with risk factors for the
development of breast cancer.
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